Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more
Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Total Assets
Latest total assets as of September 2025: CN¥5.32 Billion CNY
Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) holds total assets worth CN¥5.32 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vcanbio Cell & Gene Engineering Corp Ltd - Total Assets Trend (1992–2024)
This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vcanbio Cell & Gene Engineering Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Vcanbio Cell & Gene Engineering Corp Ltd's total assets of CN¥5.32 Billion consist of 46.8% current assets and 53.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 29.1% |
| Accounts Receivable | CN¥628.06 Million | 12.0% |
| Inventory | CN¥232.19 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥158.77 Million | 3.0% |
| Goodwill | CN¥702.91 Million | 13.4% |
Asset Composition Trend (1992–2024)
This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vcanbio Cell & Gene Engineering Corp Ltd's current assets represent 46.8% of total assets in 2024, a decrease from 62.0% in 1992.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2024, up from 8.1% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 1992.
- Asset Diversification: The largest asset category is goodwill at 13.4% of total assets.
Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Total Assets
Key competitors of Vcanbio Cell & Gene Engineering Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vcanbio Cell & Gene Engineering Corp Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vcanbio Cell & Gene Engineering Corp Ltd generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Vcanbio Cell & Gene Engineering Corp Ltd generates $ 1.91 in net profit.
Vcanbio Cell & Gene Engineering Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 1.66 | 1.47 |
| Quick Ratio | 1.60 | 1.48 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.12 Billion | CN¥ 972.59 Million | CN¥ 615.09 Million |
Vcanbio Cell & Gene Engineering Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Vcanbio Cell & Gene Engineering Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | CN¥5.25 Billion |
| Market Capitalization | $1.38 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Vcanbio Cell & Gene Engineering Corp Ltd's assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Vcanbio Cell & Gene Engineering Corp Ltd's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2024)
The table below shows the annual total assets of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.25 Billion | -3.00% |
| 2023-12-31 | CN¥5.41 Billion | +2.40% |
| 2022-12-31 | CN¥5.28 Billion | +4.99% |
| 2021-12-31 | CN¥5.03 Billion | +3.15% |
| 2020-12-31 | CN¥4.88 Billion | -0.18% |
| 2019-12-31 | CN¥4.89 Billion | +10.02% |
| 2018-12-31 | CN¥4.44 Billion | +48.12% |
| 2017-12-31 | CN¥3.00 Billion | -0.12% |
| 2016-12-31 | CN¥3.00 Billion | +6.66% |
| 2015-12-31 | CN¥2.82 Billion | +16.52% |
| 2014-12-31 | CN¥2.42 Billion | +62.76% |
| 2013-12-31 | CN¥1.48 Billion | +20.39% |
| 2012-12-31 | CN¥1.23 Billion | +45.53% |
| 2011-12-31 | CN¥847.56 Million | +9.83% |
| 2010-12-31 | CN¥771.69 Million | +10.25% |
| 2009-12-31 | CN¥699.94 Million | +7.40% |
| 2008-12-31 | CN¥651.74 Million | +10.72% |
| 2007-12-31 | CN¥588.65 Million | +1.60% |
| 2006-12-31 | CN¥579.39 Million | +18.78% |
| 2005-12-31 | CN¥487.80 Million | -12.72% |
| 2004-12-31 | CN¥558.90 Million | -12.13% |
| 2003-12-31 | CN¥636.09 Million | +12.10% |
| 2002-12-31 | CN¥567.42 Million | -27.38% |
| 2001-12-31 | CN¥781.36 Million | +15.19% |
| 2000-12-31 | CN¥678.36 Million | +2.88% |
| 1999-12-31 | CN¥659.36 Million | -2.05% |
| 1998-12-31 | CN¥673.16 Million | +10.99% |
| 1997-12-31 | CN¥606.51 Million | +40.65% |
| 1996-12-31 | CN¥431.22 Million | +8.89% |
| 1995-12-31 | CN¥396.03 Million | +40.93% |
| 1994-12-31 | CN¥281.02 Million | +54.30% |
| 1993-12-31 | CN¥182.13 Million | +52.56% |
| 1992-12-31 | CN¥119.38 Million | -- |